The firm is validating two biomarkers that it hopes will stratify patients for its investigational drug for pediatric minimally verbal autism.
Tissue-agnostic drug development approaches have their own set of scientific and financial considerations, but some drugmakers are taking on those challenges.
The company, which is also backed by Health Innovation Manchester, aims to expedite the commercialization of biomarkers into new diagnostic tests.
Canopy aims to use Zellkraftwerk's microfluidic cell-capture technology to further develop drug-development research and biomarker discovery.
The South Korean companies have also agreed to work together on the development of exosome-based biomedical products including diagnostics and therapeutics.
The companies will combine their respective technologies to create a biomarker and companion diagnostic development service for pharmaceutical customers.
Investigators found methylation models in conserved ribosomal DNA from mice also showed promise as age predictors in canine and human samples.
Researchers identified PTEN mutations, MAP kinase pathway alterations, and other features linked to anti-PD-1 response in individuals with the brain cancer.
The company is working with partners to identify new biomarkers and treatments as well as to collect utility evidence for its current coaching model.
The company is developing a methylated DNA biomarker that will predict all-cause mortality risk and risk of developing certain age-related diseases.
Within the country's first whole-genome sequencing program, researchers hope to initially focus on identifying markers associated with hereditary diseases and cancer risk.
The team compiled these proteins in three panels that could help researchers better assess plasma sample quality in protein biomarker work.
Biocept will offer patient data from its liquid biopsy tests to Prognos, who will apply artificial intelligence to ensure that patients receive correct therapies.
The researchers will not only explore tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.
The company said it will use the award to further develop its ImmuneProfiler neoantigen prediction technology for personalized cancer medicine.
The company, which went public in 2017, generates all its revenues through its epigenetic biomarker research and development partnerships.
Janssen R&D will use BiomX's microbiome-based biomarker discovery platform to identify IBD patients likely to respond to a particular therapy.
Researchers have shown nanoparticles can enrich low molecular weight, low abundance plasma proteins that are hard to detect using standard proteomic workflows.
The company said its test is the first biomarker-based diagnostic for IBD that predicts long-term disease outcome in Crohn's disease and ulcerative colitis.
The researchers will combine genomic analysis with environmental and mobile device data from 1,200 participants to try to better understand the disease.
The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.
A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.
The Los Angeles Times reports that only a third of California students meet the state's new science standards.
In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.